Vaxil Provides Update on In Vivo Study
August 27 2020 - 9:51AM
VAXIL BIO LTD. (“
Vaxil” or the
“
Company”) (TSX VENTURE: VXL), an innovative
immunotherapy biotech company specializing in cancer and infectious
diseases, would like to provide an update on the following:
On July 20, 2020, the Company announced the
commencement of the in vivo (animal) study for Vaxil’s COVID-19
vaccine candidate (Corvax™), under the guidance of Dr. Hagin,
Director of the Allergy and Clinical Immunology Unit at the Tel
Aviv Medical Center. The experiment was designed to evaluate the
immune response to Vaxil’s Corvax™ and was commenced with the
first animal injection administered on July 14, 2020.
Over the last few weeks, Corvax™ injections
were administered and are now complete. The Company is now
proceeding to evaluate the results and expects to complete this
process including analyses during the next four to six weeks, at
which time it will announce results and next steps.
“We are acutely aware that the market in
general, and our shareholders specifically, are anticipating our
progress, and would like more frequent updates, however, the nature
of the science is such that experiments take time and cannot be
accelerated,” said David Goren, Vaxil’s Chairman and Chief
Executive Officer, and continued, “we will continue to apply best
practice in our science and update shareholders when we have
credible and meaningful information to report.”
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech
company focused on its novel approach to targeting prominent cancer
markers and infectious diseases. Its lead product ImMucin™
successfully completed a Phase 1/2 clinical trial in multiple
myeloma for which it received orphan drug status from the FDA and
EMA. The company aims to continue to develop ImMucin™, a COVID-19
and a tuberculosis vaccine / treatment that has demonstrated
promising preliminary results with further preclinical evaluation
planned. Additional indications and mAb candidates are under
evaluation as immuno-oncology and infectious disease treatments
alone and in combination with other treatments.
Vaxil exploits the unique properties of signal
peptide domains on crucial proteins to develop targeted therapies
against cancer targets and infectious disease pathogens. These
signal peptide domains are identified by VaxHit™, Vaxil’s
proprietary bioinformatic approach. These signal pepdies induce a
robust T- and B-cell response across wide and varied HLA subtypes,
while acting as true, universal neoantigens. The peptide platform
targets these cells by “educating” or specifically activating the
immune system to recognize and attack the affected cells. In
addition, Vaxil’s mAb platform directly recognizes the target
protein expressed on malignant cells and recruits other elements of
the immune system to lyse those cells.
The Company is not making any express or implied
claims that it has completed developing or will be successful in
developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer: The Company cautions that COVID-19
Vaccine Development is still under early stage research and
development and is not making any express or implied claims that it
has the ability to eliminate the COVID-19 virus at this time. The
TSX Venture Exchange Inc. has in no way passed upon the merits of
the Company and has neither approved nor disapproved the contents
of this press release. This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors - including the
availability of funds, the results of financing efforts, the
results of exploration activities -- that could cause actual
results to differ materially from the Company's expectations are
disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. This press
release does not constitute an offer to sell or a solicitation of
an offer to sell any of the securities described herein in the
United States or elsewhere. These securities have not been, and
will not be, registered in the United States Securities Act of
1933, as amended, or any state securities laws, and may not be
offered or sold in the United States or to U.S. persons unless
registered or exempt therefrom.
CONTACT INFORMATIONFor further information please
visit http://vaxil-bio.com/ or contact: David Goren, CEO
-- info@vaxil-bio.com, +972 (52) 720-6000
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Apr 2023 to Apr 2024